ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary
Leuven, Belgium – ThromboGenics NV announced today that it will give a presentation at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting, which is being held in Budapest, Hungary from May 25-27.
The presentation “Targeting placental growth factor attenuates retinal permeability and inflammation in diabetic Akimba mice” which will be given by ThromboGenics’ scientist Dr. Tjing-Tjing Hu, will provide further pre-clinical evidence supporting the development of THR- 317. The presentation will take place at 10.00am CET, Friday 26 May.
THR-317 is a monoclonal antibody targeting placental growth factor (PlGF), which is being developed for the treatment of diabetic macular edema (DME) as a stand-alone or as a combination therapy with current anti-VEGF drugs. ThromboGenics is currently recruiting patients into a Phase II clinical trial for THR-317 in Europe. First data from this study are expected in Q1 2018.
“We are pleased to have the opportunity to present our cutting-edge research in the field of diabetic eye disease at this important meeting”, said Dr. Patrik De Haes, CEO of ThromboGenics nv. “There is a clear unmet medical need for improved treatment options for diabetic eye disease. ThromboGenics is focused on addressing this need and is developing multiple new therapies, including THR-317, each with the potential to improve on the current standard of care for a range of diabetic eye disease indications.”